JP2021510733A - がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ - Google Patents

がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ Download PDF

Info

Publication number
JP2021510733A
JP2021510733A JP2020558865A JP2020558865A JP2021510733A JP 2021510733 A JP2021510733 A JP 2021510733A JP 2020558865 A JP2020558865 A JP 2020558865A JP 2020558865 A JP2020558865 A JP 2020558865A JP 2021510733 A JP2021510733 A JP 2021510733A
Authority
JP
Japan
Prior art keywords
oxohexyl
aminophenylamino
alkyl
rings
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558865A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019140322A5 (https=
JP2021510733A5 (https=
Inventor
ホルソン，エドワード
ナクト，マリアーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kdac Therapeutics Inc
Original Assignee
Kdac Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kdac Therapeutics Inc filed Critical Kdac Therapeutics Inc
Publication of JP2021510733A publication Critical patent/JP2021510733A/ja
Publication of JPWO2019140322A5 publication Critical patent/JPWO2019140322A5/ja
Publication of JP2021510733A5 publication Critical patent/JP2021510733A5/ja
Priority to JP2024015651A priority Critical patent/JP2024099510A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020558865A 2018-01-12 2019-01-11 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ Pending JP2021510733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015651A JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616831P 2018-01-12 2018-01-12
US62/616,831 2018-01-12
PCT/US2019/013375 WO2019140322A1 (en) 2018-01-12 2019-01-11 Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015651A Division JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Publications (3)

Publication Number Publication Date
JP2021510733A true JP2021510733A (ja) 2021-04-30
JPWO2019140322A5 JPWO2019140322A5 (https=) 2022-02-08
JP2021510733A5 JP2021510733A5 (https=) 2022-02-08

Family

ID=65516716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558865A Pending JP2021510733A (ja) 2018-01-12 2019-01-11 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP2024015651A Pending JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015651A Pending JP2024099510A (ja) 2018-01-12 2024-02-05 がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ

Country Status (7)

Country Link
US (2) US12128018B2 (https=)
EP (1) EP3737362B1 (https=)
JP (2) JP2021510733A (https=)
CN (1) CN112135610A (https=)
CA (1) CA3125731A1 (https=)
ES (1) ES3057234T3 (https=)
WO (1) WO2019140322A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023101505A1 (ko) * 2021-12-03 2023-06-08 연세대학교 산학협력단 Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701699B1 (en) * 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
US20240226039A1 (en) * 2021-05-24 2024-07-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune checkpoint inhibitor and hdac inhibitor combination therapy strategy
WO2023034440A1 (en) 2021-09-01 2023-03-09 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors
CN113754587B (zh) * 2021-09-22 2023-07-14 沈阳药科大学 一种苯基吡唑类化合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514261A (ja) * 2011-02-28 2014-06-19 レプリジェン コーポレーション ヒストン脱アセチル化酵素阻害剤
JP2014523857A (ja) * 2011-04-28 2014-09-18 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2015528812A (ja) * 2012-07-27 2015-10-01 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
US20160272579A1 (en) * 2013-11-05 2016-09-22 Dana-Farber Cancer Institute, Inc. Inhibitors of histone deacetylase
US9796664B2 (en) * 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE670584C (de) 1936-07-09 1939-01-20 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von o-Aminophenolen
DE1108213B (de) 1959-02-28 1961-06-08 Frantisek Sorm Dr Ing Verfahren zur Herstellung von 2, 2-Dimethyl-3-phenylcyclopropan-carbonsaeuren
SE370866B (https=) 1968-03-21 1974-11-04 Ciba Geigy Ag
JPS4825500B1 (https=) 1970-12-29 1973-07-30
US3850931A (en) 1971-06-25 1974-11-26 American Home Prod 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters
GB2079480B (en) 1980-07-08 1984-05-16 Kodak Ltd Heat-activated photographic and thermal recording processes employing precursor compounds
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
JPS57102887A (en) 1980-12-18 1982-06-26 Otsuka Pharmaceut Co Ltd Preparation of benzo(ij)quinolizine-2-carboxylic acid derivative
US4404356A (en) 1981-09-09 1983-09-13 Ciba-Geigy Corporation Heat-curable epoxide resin compositions
JPS5853916A (ja) 1981-09-09 1983-03-30 チバ−ガイギ−・アクチエンゲゼルシヤフト 熱硬化性エポキシド樹脂組成物
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
DE3511110A1 (de) 1985-03-27 1986-10-02 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
GB8508588D0 (en) 1985-04-02 1985-05-09 Akzo Nv Indene & napthalene derivatives
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
DE3830054A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
JPH03232868A (ja) 1990-02-05 1991-10-16 Nippon Telegr & Teleph Corp <Ntt> 新規光学活性化合物及び液晶組成物
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
JPH06122669A (ja) 1991-12-28 1994-05-06 Ishihara Sangyo Kaisha Ltd ジアミノベンゼン誘導体を含有するホスホリパーゼａ２阻害剤
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JPH09227495A (ja) 1996-02-16 1997-09-02 Tanabe Seiyaku Co Ltd フェノール誘導体及びその製法
EP1014962A4 (en) 1997-06-26 2007-06-27 Lilly Co Eli ANTITHROMBOTIC AGENTS
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
FR2805741B1 (fr) 2000-03-06 2003-06-20 Oreal Composition de teinture d'oxydation des fibres keratiniques avec un derive particulier de la paraphenylenediamine et un colorant direct particulier
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
AU2001287000A1 (en) 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
JP4183923B2 (ja) 2001-03-29 2008-11-19 富士フイルム株式会社 熱現像感光材料
SK13682003A3 (sk) 2001-04-12 2004-07-07 F. Hoffmann-La Roche Ag Dihydrobenzo[b][1,4]diazepin-2-ónové deriváty ako mGluR2 antagonisty II
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
WO2005025557A1 (en) 2003-09-16 2005-03-24 Monash University An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2005033562A2 (en) * 2003-10-02 2005-04-14 Jesel, Inc. Double roller cam follower
WO2005034880A2 (en) 2003-10-09 2005-04-21 Aton Pharma, Inc. Thiophene and benzothiophene hydroxamic acid derivatives
US20080070954A1 (en) 2003-10-27 2008-03-20 S*Bio Pte Ltd. Acylurea Connected And Sulfonylurea Connected Hydroxamates
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006001958A2 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
US20060008517A1 (en) 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
KR20070057822A (ko) 2004-08-09 2007-06-07 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 (ｈｄａｃ) 억제제 활성을 갖는히드록시아미드 화합물
JPWO2006028161A1 (ja) 2004-09-09 2008-05-08 財団法人乙卯研究所 セロトニン５−ｈｔ３受容体作動薬
JP2008546793A (ja) 2005-06-24 2008-12-25 メルク エンド カムパニー インコーポレーテッド 修飾マロン酸誘導体
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1973405A4 (en) 2006-01-12 2011-06-01 Merck Sharp & Dohme HYDROXYALKYLARYLAMID DERIVATIVES
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
CA2670645A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
CN103087043A (zh) 2007-03-16 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
EP2170882A1 (en) 2007-06-26 2010-04-07 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
EP2209765A4 (en) 2007-10-22 2010-12-01 Orchid Res Lab Ltd HISTONE DEACETYLASE INHIBITORS
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
WO2009076234A2 (en) 2007-12-07 2009-06-18 University Of Maryland, Baltimore Synthesis methods of histone deacetylase inhibitors (hdacis)
WO2009104819A1 (en) 2008-02-22 2009-08-27 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
WO2010014054A1 (en) 2008-07-28 2010-02-04 The Regents Of The University Of California Inhibitors of protein prenyltransferases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
CA2745073A1 (en) 2008-12-03 2010-06-10 Li-Huei Tsai Inhibition of hdac2 to promote memory
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
CA2751777A1 (en) 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Novel ortho-aminoamides for the treatment of cancer
BRPI1010974A2 (pt) 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP2012529449A (ja) 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
IN2012DN00999A (https=) 2009-07-16 2015-04-10 Vertex Pharma
WO2011053876A1 (en) 2009-10-30 2011-05-05 Massachusetts Institute Of Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20140107166A1 (en) 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102775356B (zh) 2011-05-13 2015-07-22 江苏恒谊药业有限公司 4-氨基喹唑啉衍生物及其应用
US9294896B2 (en) 2011-07-05 2016-03-22 Zia Shlaimoun Method and system for video messaging
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013059582A2 (en) 2011-10-20 2013-04-25 Nupotential, Inc. Small molecule inhibitors of histone deacteylases
WO2013067391A1 (en) 2011-11-02 2013-05-10 The Broad Institute, Inc. Fluorescent substrates for determining lysine modifying enzyme activity
CA2759407A1 (en) 2011-12-02 2013-06-02 Marrett Alexander GREEN Grey water recycling systems and valves
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
US20160346240A1 (en) 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018132391A1 (en) 2017-01-10 2018-07-19 Dana-Farber Cancer Institute, Inc. Compositions and methods using an epigenetic inhibitor
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9796664B2 (en) * 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
JP2014514261A (ja) * 2011-02-28 2014-06-19 レプリジェン コーポレーション ヒストン脱アセチル化酵素阻害剤
JP2014523857A (ja) * 2011-04-28 2014-09-18 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2015528812A (ja) * 2012-07-27 2015-10-01 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
US20160272579A1 (en) * 2013-11-05 2016-09-22 Dana-Farber Cancer Institute, Inc. Inhibitors of histone deacetylase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR IMMUNOLOGY, vol. 87, JPN6023005553, 2017, pages 227 - 239, ISSN: 0005295033 *
PP.E854-E855, THE JOURNAL OF UROLOGY, vol. 197, JPN6023005555, 2017, pages 65 - 07, ISSN: 0005295032 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023101505A1 (ko) * 2021-12-03 2023-06-08 연세대학교 산학협력단 Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물

Also Published As

Publication number Publication date
CA3125731A1 (en) 2019-07-18
CN112135610A (zh) 2020-12-25
US20250255839A1 (en) 2025-08-14
WO2019140322A1 (en) 2019-07-18
US20190216754A1 (en) 2019-07-18
TW201938149A (zh) 2019-10-01
US12128018B2 (en) 2024-10-29
EP3737362A1 (en) 2020-11-18
JP2024099510A (ja) 2024-07-25
ES3057234T3 (en) 2026-02-27
US20210177781A9 (en) 2021-06-17
EP3737362B1 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
JP2021510733A (ja) がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
US20220227734A1 (en) Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
JP7643874B2 (ja) がん幹細胞を標的化するがん治療
AU2015360416A1 (en) Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12109207B2 (en) Methods of using 4(1H)-quinolone derivatives
US10865213B2 (en) Max binders as MYC modulators and uses thereof
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
JP2022516745A (ja) Ｄｏｔ１ｌ分解剤およびその使用
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
HK40041778A (en) Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240301

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406